🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to researchers.

An International Health Concern

Gonorrhoea infections are on the rise worldwide, with figures suggesting in excess of 82 million instances per year. Especially elevated rates are reported in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in close succession. This drug, which is employed against UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This authorization signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Outcomes and Worldwide Availability

As per results released by a major medical journal, the new drug cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which combines an injection and a pill. The trial included hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in numerous low-income and middle-income countries.

Doctors directly involved have expressed hope. Access to a single-dose, oral treatment like this is described as a "critical tool" for managing the epidemic. This is viewed as essential to reduce the burden of the infection for people and to prevent the spread of extremely resistant gonorrhoea around the world.